Report Interpretation

Overview

This report reviews Sino Biopharmaceutical's 1H26 results. Although revenue growth was below Goldman Sachs' expectations, the ramp-up of innovative drugs, reductions in selling and R&D expenses, and BD income jointly drove an earnings beat. Goldman Sachs consequently raises its earnings forecasts and target price and remains positive on earnings resilience over the next two years.

Core views

1H26 revenue was RMB19.4 billion, up 10.6% year over year, below Goldman Sachs' prior estimate of 14%. Excluding collaboration income related to the Sanofi transaction, underlying product sales grew approximately 5% year over year, indicating weaker-than-expected commercial execution. Generic drug sales increased only 1% year over year, mainly due to pricing pressure from volume-based procurement renewals and a more cautious prescribing environment amid the recent intensification of anti-corruption efforts. By contrast, innovative product revenue grew 29% year over year, with the rapid ramp-up of newly launched oncology products serving as the primary driver, including zongertinib (HER2 TKI), a CDK2/4/6 inhibitor, a KRAS G12C inhibitor, and a PD-L1 product. Management remains confident in achieving double-digit FY26 revenue growth including the contribution from BD income and believes that additional out-licensing transactions could provide further upside. Weak revenue performance did not prevent earnings from exceeding expectations. 1H26 net profit reached RMB3.4 billion, up 1.4% year over year and significantly above Goldman Sachs' estimate of RMB2.2 billion, mainly due to expense optimization. Selling expenses declined 18% year over year, with the selling expense ratio falling from 36.7% of product sales in 1H25 to 28%. The report attributes this to fewer physician engagement activities amid the anti-corruption environment and the company's continued efficiency initiatives, including using AI to improve commercial productivity and operational efficiency. R&D expenses also declined 3.4% year over year because the company streamlined less competitive projects following a pipeline review led by the new CMO. Supported by operating leverage and BD income, adjusted core earnings excluding the Sinovac dividend grew 92% year over year. Even after further excluding BD income, Goldman Sachs estimates that underlying core earnings still grew approximately 63%, demonstrating resilient profitability despite weaker revenue. Regarding the R&D pipeline, the report highlights that the company is developing more highly differentiated next-generation programs. In chronic diseases, the dual-target siRNA HJY-22 targets both PCSK9 and Lp(a), is scheduled to file an IND in 1Q27, and has the potential for once-yearly dosing. Preclinical data show that its lipid-lowering efficacy is comparable to the combined use of two single-target siRNAs, supporting its potential as a next-generation ASCVD therapy. In oncology, the PD-1/IL-2 fusion protein TQB6628 is scheduled to file an IND in 4Q26. Its dual-domain affinity engineering is designed to enhance effector T-cell activation and reduce Treg binding; according to company disclosures, its preclinical efficacy is superior to IBI363 and RG6279. The dual-target ADC candidate TRD120 targets CEA and CDH17 and is scheduled to file an IND in 1H27. Its dual-target design may help overcome tumor heterogeneity, while its exatecan payload may address DXd-related resistance. Management reiterated its development pace of approximately 20 IND filings per year and highlighted catalysts including Phase 1 data for Kylo-11 (Lp(a) siRNA) and preclinical data for the STAT6 PROTAC program. These developments could also support future BD opportunities. Following the results announcement, Goldman Sachs raised its 2026, 2027, and 2028 earnings forecasts by 21%, 14%, and 9%, respectively, because expense reductions were stronger than previously assumed, despite weaker revenue growth. The table shows new revenue forecasts for 2026—2028 of RMB36.0058 billion, RMB38.0640 billion, and RMB40.0774 billion, respectively, compared with prior forecasts of RMB37.8027 billion, RMB42.0059 billion, and RMB46.2618 billion. New EPS forecasts for the same period are RMB0.28, RMB0.30, and RMB0.32, respectively, compared with prior forecasts of RMB0.24, RMB0.26, and RMB0.29. This combination reflects the report's core judgment: revenue expectations have been lowered, but more aggressive expense control has resulted in higher profit forecasts. The corresponding forecast P/E multiples for 2026—2028 are 14.5x, 13.9x, and 12.9x, respectively. Goldman Sachs raises its 12-month target price from HK$8.41 to HK$8.65. The target price is based on a sum-of-the-parts valuation: the innovative drug pipeline is valued at HK$96.3 billion using DCF; the generic drug business is valued at HK$59.9 billion based on a 10.0x exit P/E multiple and a five-year CAGR of 5%; and the anlotinib and PD-(L)1 portfolio is valued at HK$6.0 billion using DCF. Based on the closing price of HK$4.79 on August 19, 2026, the target price implies 80.5% upside. The longer-term Buy thesis includes resilient earnings growth over the next two years, ample cash that could support additional BD transactions, and valuation at the low end of its historical five-year range. For generic drugs, the report believes that liver disease products have reflected most of the negative impact from volume-based procurement since 2019, with the future impact becoming more neutral, while more than 100 new generic drug launches expected over the next three years could generate incremental sales. Recent innovative drug drivers also include PD-1/L1, G-CSF, ROS1 and ALK inhibitors, bepirovirsen, and several biosimilars. However, Goldman Sachs remains cautious about challenges in allocating R&D resources among the group's subsidiaries.

Analysis framework

Goldman Sachs first compares 1H26 revenue and profit with its own forecasts, then breaks revenue down into generic drugs, innovative drugs, and collaboration income to identify the sources of growth. It subsequently analyzes selling expenses, R&D expenses, BD income, and the Sinovac dividend to assess the extent of underlying earnings improvement. The report then evaluates the R&D pipeline based on preclinical results, IND timelines, and potential BD catalysts, before adjusting revenue and earnings forecasts and deriving the 12-month target price through separate valuations of innovative drugs, generic drugs, and the anlotinib and PD-(L)1 portfolio. Data sources include company data, Goldman Sachs Research estimates, and FactSet.

Methodology notes

• Valuation MethodologySOTP Valuation

  Sum-of-the-parts valuation

  The report separately estimates the value of the innovative drug pipeline, generic drug business, and the anlotinib and PD-(L)1 portfolio, then adds the components together to derive a 12-month target price of HK$8.65.

• Valuation MethodologyDCF

  DCF valuation of innovative drug assets

  The report assesses the innovative drug pipeline and the anlotinib and PD-(L)1 portfolio by discounting future cash flows, assigning valuations of HK$96.3 billion and HK$6.0 billion, respectively.

• Valuation MethodologyPE/PEG valuation

  Exit P/E valuation

  The generic drug business is valued at HK$59.9 billion using a 10.0x exit P/E multiple and a five-year CAGR of 5%.

• Company Fundamentals and Financial FrameworkEarnings Quality Analysis

  Layered exclusions from core earnings

  The report first excludes the Sinovac dividend and then further excludes BD income to distinguish one-off or non-underlying contributions from operating earnings improvement, resulting in conclusions of 92% adjusted core earnings growth and approximately 63% underlying core earnings growth.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sino Biopharmaceutical (1177.HK)

  The report's primary research subject; innovative product growth, expense optimization, and BD income drove an earnings beat, and Goldman Sachs assigns a Buy rating.

  Strengths

  Innovative product revenue grew 29% year over year, expense ratios declined significantly, underlying core earnings grew approximately 63%, and cash resources could support additional BD transactions.

  Weaknesses

  Underlying product sales grew approximately 5%, generic drugs increased only 1%, commercial execution was weaker than expected, and internal allocation of R&D resources across the group remains challenging.

  Comparison

  The report states that the company's valuation is at the low end of its historical five-year range.

  Risks

  Broader price reductions for generic drugs, delays in approvals for key products, low returns caused by improper allocation of R&D resources, and a weaker-than-expected ramp-up of innovative drugs.

• Sanofi

  Sanofi has a collaboration transaction with Sino Biopharmaceutical, with related collaboration income included in revenue for the reporting period.

  Strengths

  Collaboration income contributes to FY26 revenue growth.

  Weaknesses

  Excluding this collaboration income, underlying product sales grew only approximately 5% year over year.

Key data

• 1H26 RevenueRMB19.4 billionUp 10.6% year over year, below Goldman Sachs' forecast growth of 14%
• Underlying Product Sales GrowthApproximately 5%Year-over-year growth excluding collaboration income from the Sanofi transaction
• Innovative Product Revenue Growth29%Year-over-year growth driven by the ramp-up of newly launched oncology products
• Generic Drug Sales Growth1%Year-over-year growth affected by pricing pressure from volume-based procurement renewals and a cautious prescribing environment
• 1H26 Net ProfitRMB3.4 billionUp 1.4% year over year and above Goldman Sachs' estimate of RMB2.2 billion
• Selling ExpensesDown 18% year over yearThe selling expense ratio declined from 36.7% in 1H25 to 28% of product sales
• R&D ExpensesDown 3.4% year over yearLess competitive projects were streamlined following the pipeline review
• Adjusted Core Earnings Growth92%Year-over-year growth excluding the Sinovac dividend
• Underlying Core Earnings GrowthApproximately 63%Goldman Sachs estimate after further excluding BD income
• 2026—2028 Earnings Forecast Revisions+21% / +14% / +9%Expense reductions were stronger than previously assumed
• 2026—2028 Revenue ForecastsRMB36.0058 billion / RMB38.0640 billion / RMB40.0774 billionPrior forecasts were RMB37.8027 billion / RMB42.0059 billion / RMB46.2618 billion
• 2026—2028 EPS ForecastsRMB0.28 / RMB0.30 / RMB0.32Prior forecasts were RMB0.24 / RMB0.26 / RMB0.29
• 2026—2028 Forecast P/E14.5x / 13.9x / 12.9xBased on the report's updated forecasts
• 12-Month Target PriceHK$8.65Raised from HK$8.41; implies 80.5% upside from the current price of HK$4.79
• Innovative Drug Pipeline ValuationHK$96.3 billionBased on DCF valuation
• Generic Drug Business ValuationHK$59.9 billionBased on a 10.0x exit P/E multiple and a five-year CAGR of 5%
• Anlotinib and PD-(L)1 ValuationHK$6.0 billionBased on DCF valuation
• R&D Development PaceApproximately 20 IND filings per yearPipeline development pace reiterated by management

Impact & implications

The report believes that the company faces near-term pressure on commercial execution and generic drug growth, but the ramp-up of innovative drugs and expense discipline have significantly improved earnings elasticity. If FY26 double-digit revenue growth, new drug development milestones, and additional BD transactions materialize as planned, earnings resilience could continue over the next two years. However, the valuation thesis still depends on the ramp-up of innovative drugs, timely pipeline approvals, and effective allocation of R&D resources.

Risks

• Broader price reductions across the generic drug portfolio.
• Delays in regulatory approvals for key pipeline products.
• Improper allocation of R&D resources, resulting in low returns on R&D investment.
• Slower-than-expected sales ramp-up after innovative drug launches.

What to watch

• Whether management can achieve double-digit FY26 revenue growth including BD income.
• Whether additional new out-licensing transactions emerge.
• Whether TQB6628 can file an IND in 4Q26 as planned.
• Whether HJY-22 can file an IND in 1Q27 as planned.
• Whether TRD120 can file an IND in 1H27 as planned.
• Disclosure of Phase 1 data for Kylo-11 and preclinical data for the STAT6 PROTAC program.
• The ramp-up of innovative drugs and progress in launching more than 100 new generic drugs over the next three years.